在药物耐药性中,对流动神经刺激的成本效益分析
Weixi Xiong1, Lu Lu1, Yingying Zhang1
1Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, 610041, China.
Acta epileptologica
|November 1, 2025
概括
神经刺激 (VNS) 是一种具有成本效益的药物耐药性的治疗方法,可以降低医疗费用并改善患者的生活质量. 这种疗法提供了显著的长期经济效益,尽管最初的投资.
科学领域:
- 神经学 神经学
- 卫生经济学 卫生经济学
背景情况:
- 影响全球5000万,其中30%的人尽管服用抗发作药物 (ASM),但仍患有耐药性 (DRE).
- 耐药性导致生活质量下降,死亡率增加,社会经济负担显著.
- 自1997年以来,神经刺激 (VNS) 是一种已建立的DRE神经刺激疗法,可减少发作并改善生活质量.
研究的目的:
- 在DRE患者中进行VNS的综合性成本效益分析.
- 检查VNS治疗的直接医疗成本,间接社会成本和长期经济效益.
- 确定影响VNS成本效益的因素,并提出优化策略.
主要方法:
- 对DRE中VNS的成本效益分析的文献综述.
- 分析直接的医疗成本 (植入,维护) 和间接的社会成本 (生产力损失).
- 评估长期经济效益和减少医疗保健使用率.
主要成果:
- 维纳斯疗法显示出显著的长期成本效益,特别是在发达国家.
- 该疗法减少了医疗保健利用率,药物费用和与不受控制的相关的社会经济负担.
- 大约50-60%的患者经历了超过50%的发作频率减少与VNS.
结论:
- 对于DRE来说,VNS是一种有价值的治疗选择,提供了长期的经济效益.
- 优化VNS疗法可以增强其对各种医疗保健系统和患者群体的价值主张.
- 维纳斯改善了控制,情绪,认知和生活质量,特别是在非手术候选人中.
相关概念视频
01:26Neurochemical Transmission: Sites of Drug Action
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:15Factors Affecting Drug Distribution: Organ Perfusion Rate
Drug distribution within the body is a complex process influenced by several factors, including perfusion rate, the rate at which the bloodstream transports drugs to tissue. This limitation becomes particularly significant when dealing with highly lipophilic drugs. In such cases, the rate at which the drug can move across membranes is crucial, and if the membrane is highly permeable to the drug, distribution becomes rate-limited by perfusion.
Perfusion rate-limited distribution relies on the...
Perfusion rate-limited distribution relies on the...
00:57Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models
Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...
01:20Measurement of Bioavailability: Pharmacodynamic Methods
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).